关键词: ¹²⁵I粒子植入, 化疗, 复发性卵巢癌, 联合治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy and safety of ultrasound-guided iodine-125(¹²⁵I)seed implantation combined with chemotherapy in the treatment of recurrent ovarian cancer at the vaginal stump,and to evaluate its impact on patients′ quality of life. Methods A retrospective analysis was conducted on the clinical data of 54 patients with recurrent ovarian cancer at the vaginal stump admitted to Harbin Medical University Cancer Hospital from January 2010 to December 2023.The patients were divided into the study group(¹²⁵I seed implantation combined with chemotherapy,n=27)and the control group(chemotherapy alone,n=27)according to the treatment method.Both groups received a standardized chemotherapy with paclitaxel combined with carboplatin,and were followed up until 12 months after treatment.The short-term objective remission rate(ORR),disease control rate(DCR),levels of serum tumor marker(CEA and CA125),target lesion size,pain relief,Karnofsky performance status(KPS)scores,Functional Assessment of Cancer Therapy-Ovary(FACT-O)scores,and incidence of adverse reactions were compared between the two groups. Results After treatment,the ORR in the study group was significantly higher than that in the control group(100.00% vs. 40.74%,P＜0.001);there was no significant difference in DCR between the two groups(100.00% vs. 85.19%,P=0.119).At 3,6,9,and 12 months after treatment,the levels of serum CEA and CA125 in the study group were significantly lower than those in the control group(P＜0.001).At 9 and 12 months after treatment,the mean maximum diameter of target lesions in the study group was significantly smaller than that in the control group(P＜0.01).The pain relief rate in the study group(92.00%)was higher than that in the control group(72.00%),but the difference was not statistically significant(P=0.141).At 12 months after treatment,the KPS score and total FACT-O score in the study group were better than those in the control group(P=0.034).Treatment-related adverse events in both groups mainly included fever, abdominal pain, and nausea/vomiting. In the study group, fever, abdominal pain, and nausea/vomiting occurred in 1, 2, and 1 patient(s), respectively, whereas in the control group, the corresponding numbers were 2, 1, and 2. No serious adverse events were observed in either group. Conclusion Ultrasound-guided ¹²⁵I seed implantation combined with chemotherapy can significantly improve the local tumor response rate,functional status,and quality of life in patients with recurrent ovarian cancer at the vaginal stump,and is safe and effective as an individualized treatment option for such patients.

Key words: ¹²⁵I seed implantation, chemotherapy, recurrent ovarian cancer, combined treatment